Bronchial Dilatation:
An Underestimated Respiratory Burden
Versandkostenfrei!
Versandfertig in 6-10 Tagen
40,99 €
inkl. MwSt.
PAYBACK Punkte
20 °P sammeln!
Bronchial dilatations (BDDs) result from a recurrent inflammatory process in the airways, causing irreversible changes and recurrent respiratory infections. Our retrospective study analyzed 100 patients diagnosed with DDBs between 2010 and 2020. The population was predominantly female (mean age 57.79), with a prevalence of a history of tuberculosis (40%) and recurrent respiratory infections (21%). The main symptoms were productive cough (80%) and dyspnoea (61%). Chest CT confirmed the diagnosis, revealing predominantly cylindrical and diffuse lesions. Antibiotic therapy, accompanied by respira...
Bronchial dilatations (BDDs) result from a recurrent inflammatory process in the airways, causing irreversible changes and recurrent respiratory infections. Our retrospective study analyzed 100 patients diagnosed with DDBs between 2010 and 2020. The population was predominantly female (mean age 57.79), with a prevalence of a history of tuberculosis (40%) and recurrent respiratory infections (21%). The main symptoms were productive cough (80%) and dyspnoea (61%). Chest CT confirmed the diagnosis, revealing predominantly cylindrical and diffuse lesions. Antibiotic therapy, accompanied by respiratory physiotherapy, was the treatment of choice. Predictive factors for exacerbations included a history of tuberculosis, dyspnea, hypoxemia and the presence of Pseudomonas aeruginosa. Despite therapeutic advances, DDB remains a major challenge, with a significant impact on patients' quality of life.
Andere Kunden interessierten sich für
